Chronic lymphocytic leukemia: recent advances and emerging therapeutic strategies
- 1Center for Hematologic Malignancy, National Cancer Center, 323 Ilsan-Ro, Ilsandong-Gu, Goyang, Gyeonggi 410-769 Korea
Abstract
Chronic lymphocytic leukemia (CLL) management has evolved into a precision-medicine paradigm, with genetic risk factors such as TP53 and IGHV status serving as key determinants of frontline treatment selection. The therapeutic landscape has expanded to include fixed-duration options alongside established continuous regimens. This expansion has enabled personalized management strategies incorporating measurable residual disease-guided treatment approaches aimed at achieving deeper responses while minimizing long-term toxicity and resistance. In a relapsed/refractory setting, treatment selection must be guided by prior treatment exposure, identified molecular mechanisms of resistance, and the availability of novel agents. In this review, we have synthesized the latest clinical evidence and international guidelines to provide an updated, evidence-based algorithm for the diagnosis and management of CLL. Furthermore, we examined the clinical efficacy reported in pivotal trials involving patients with relapsed/refractory CLL and discuss the potential of next-generation therapies, including non-covalent Bruton tyrosine kinase (BTK) inhibitors, BTK degraders, and cellular immunotherapies, to expand treatment options for high-risk patients. Finally, we addressed the clinical challenges of Richter’s transformation, emphasizing the importance of clonality assessment and the urgent need for further clinical trials and innovative therapeutic approaches to improve long-term outcomes in this patient population.
Related
- Emerging Therapeutic Strategies for Neurodegenerative Diseases: A Comprehensive Review of Recent Advances and Future Directions
- Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Based Genome Editing in Inherited Cardiovascular Diseases: Therapeutic Advances, Emerging Editing Platforms, and Translational Challenges
- Differential functions of ROCK1 and ROCK2 in liver fibrosis and advances in targeted therapeutic strategies
- Chronic Myeloid Leukemia Beyond BCR::ABL1 Inhibition: Resistance Mechanisms and Emerging Therapeutic Modalities.
- Contemporary and Emerging Therapeutic Strategies in Hypoparathyroidism: From Conventional Treatment to Restoration of Parathyroid Function
BibTeX
@article{jung2026chronic,
title = {{Chronic lymphocytic leukemia: recent advances and emerging therapeutic strategies}},
author = {Jongheon Jung},
journal = {Blood Research},
year = {2026},
month = nov,
doi = {10.1007/s44313-026-00183-w},
url = {https://doi.org/10.1007/s44313-026-00183-w},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Chronic lymphocytic leukemia: recent advances and emerging therapeutic strategies
AU - Jongheon Jung
PY - 2026
DA - 2026/11/03
JO - Blood Research
DO - 10.1007/s44313-026-00183-w
UR - https://doi.org/10.1007/s44313-026-00183-w
AB - Chronic lymphocytic leukemia (CLL) management has evolved into a precision-medicine paradigm, with genetic risk factors such as TP53 and IGHV status serving as key determinants of frontline treatment selection. The therapeutic landscape has expanded to include fixed-duration options alongside established continuous regimens. This expansion has enabled personalized management strategies incorporating measurable residual disease-guided treatment approaches aimed at achieving deeper responses while minimizing long-term toxicity and resistance. In a relapsed/refractory setting, treatment selection must be guided by prior treatment exposure, identified molecular mechanisms of resistance, and the availability of novel agents. In this review, we have synthesized the latest clinical evidence and international guidelines to provide an updated, evidence-based algorithm for the diagnosis and management of CLL. Furthermore, we examined the clinical efficacy reported in pivotal trials involving patients with relapsed/refractory CLL and discuss the potential of next-generation therapies, including non-covalent Bruton tyrosine kinase (BTK) inhibitors, BTK degraders, and cellular immunotherapies, to expand treatment options for high-risk patients. Finally, we addressed the clinical challenges of Richter’s transformation, emphasizing the importance of clonality assessment and the urgent need for further clinical trials and innovative therapeutic approaches to improve long-term outcomes in this patient population.
SN - 2287-979X
SN - 2288-0011
ER -